The average price reduction of insulin is close to 50%, for diabetic patients is a great benefit, the collection of insulin with the previous five collection of different, this belongs to the biological drugs, is to be by virtue of the collection of the reform process of an important milestone, and to a large extent to reduce the risk.
Selected products to reduce the rate of largeAnhui Province, public medical institutions (including the army in Anhui's medical institutions) to organize the full implementation of the selection of the results of the six countries, the centralized purchasing of medicines special (insulin) and the previous 5 in different countries, insulin belongs to the biomedicine, which means that the state organization of centralized purchasing of medicines for the first time from the scope of the expansion of the chemical drugs to the field of biological medicines is the drug important milestone in the collection and storage reform process.
The national centralized procurement of insulin was launched in Anhui Province. Unlike the previous five national centralized purchases, this insulin centralized purchase belongs to biological drugs and is an important milestone in the process of drug centralized purchase reform. It covers second and third generation insulin commonly used in clinical practice, including 16 generic names of 42 varieties. The average price of the selected products decreased by 48%, with a maximum decrease of 73%. The selected products have seen significant declines. Insulin is an important drug for the treatment of diabetes, and the large number of diabetic patients requires long-term use.
The special procurement of insulin is the first time that the centralized procurement of drugs organized by the state has been extended to the field of biological drugs. The centralized procurement covers the second and third generation insulin commonly used in clinical practice. The price of some products decreased by 48% on average and 73% at the highest. For example, the price of glucagon insulin, which has a large clinical dosage, dropped from 183.1 yuan per dose to 72 yuan per dose, and the per capita drug cost of patients can be reduced by about 3,000 yuan per year.
The insulin special collection of mainstream products such as glycemic insulin, premixed insulin, meal-time insulin, etc. have been selected, reducing the price at the same time, realizing a higher degree of match with the actual clinical needs, maintaining the stability of clinical medication and the continuity of patients' use of medication, and reducing the risk of substitution. Diabetes requires long-term management, which puts higher requirements on the stability of drug supply. The special collection and procurement of insulin attaches great importance to the stability of product supply, through capacity mapping survey, reserving enough production preparation, multiple manufacturers selected and many other measures to ensure the stability of the supply of drugs.